Immunoadhesins as research tools and therapeutic agents

Current Opinion in Immunology

Volumn 9, Issue 2, 1997, Pages 195-200

  Ashkenazi, Avi ^a   Chamow, Steven M ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN;

AUTOIMMUNITY; DRUG STRUCTURE; DRUG THERAPY; INFLAMMATORY DISEASE; REVIEW;

EID: 0030932133     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80135-5     Document Type: Article

References (50)

1. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Bym RA, Lucas C, Wurm FM, Groopman JE, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature. 337:1989;525-531.
2. Chamow SM, Ashkenazi A. Immunoadhesins: principles and applications. of outstanding interest Trends Biotechnol. 14:1996;52-60 This review lists over 50 immunoadhesins and discusses several examples of immunoadhesins with complex structures and with Fc isotypes other than γ1.
3. Strom T, Steele A, Nichols J. Genetically engineered proteins for immunoregulation. Transplant Proc. 27:1995;18-20.
4. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. of outstanding interest J Immunol. 154:1995;5590-5600 There are two unique aspects to this study. First, it uses the immunoadhesin technique to extend the circulating half-life of a cytokine that has anti-inflammatory activity and demonstrates its therapeutic potential in animal models. Second, the Fc region of the immunoadhesin (mouse Fcγ2) is rendered noncytolytic by site-directed mutations that eliminate binding to complement and to Fcγ receptors.
5. Flores-Villanueva P, Zheng X, Strom T, Stadecker M. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J Immunol. 156:1996;3315-3320.
6. Yao Z, Painter S, Fanslow W, Ulrich D, Macduff B, Spriggs M, Armitage R. Human IL-17: a novel cytokine derived from T cells. of special interest J Immunol. 155:1995;5483-5486 An example of how the immunoadhesin technique can be used to investigate the biological functions of novel proteins, in this case a secreted cytokine.
7. Culouscou JM, Carlton GW, Aruffo A. HER4 receptor activation and phosphorylation of Shc proteins by recombinant heregulin-Fc fusion proteins. J Biol Chem. 270:1995;12857-12863.
8. LaRochelle WJ, Dirsch OR, Finch PW, Cheon HG, May M, Marchese C, Pierce JH, Aaronson SA. Specific receptor detection by a functional keratinocyte growth factor-immunoglobulin chimera. of special interest J Cell Biol. 129:1995;357-366 An example of the use of a ligand immunoadhesin in immunohistochemical studies localizing the cognate receptor in tissue sections.
9. Tournay C, Courtoy P, Marodi L, Totte P, Werenne J, Jacquet A, Garcia-Quintana L, Bollen A, Moguilevsky N. Uptake of recombinant myeloperoxidase, free or fused to Fc gamma, by macrophages enhances killing activity toward micro-organisms. DNA Cell Ciol. 15:1996;617-624.
10. Beck JT, Marsters SA, Harris RJ, Carter P, Ashkenazi A, Chamow SM. Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage. Mol Immunol. 31:1994;1335-1344.
11. Hollenbaugh D, Douthwright J, McDonald V, Aruffo A. Cleavable CD40 Ig fusion proteins and the binding to sgp39. J Immunol Methods. 188:1995;1-7.
12. Gruss H, Dower S. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood. 85:1995;3378-3404.
13. Crowe PD, Van Arsdale TL, Walter BN, Ware CF, Hession C, Ehrenfels B, Browning JL, Din WS, Goodwin RG, Smith CA. A lymphotoxin-β-specific receptor. Science. 264:1994;707-710.
14. Marsters S, Sheridan J, Donahue CJ, Pitti R, Gray C, Goddard A, Bauer K, Ashkenazi A. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr Biol. 6:1996;1669-1676.
15. Bennett BD, Zeigler FC, Gu Q, Fendly B, Goddard AD, Gillett N, Matthews W. Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk. Proc Natl Acad Sci USA. 92:1995;1866-1870.
16. Shao H, Lou L, Pandey A, Verderame M, Siever D, Dixit V. cDNA cloning and characterization of a Cek7 receptor protein-tyrosine kinase ligand that is identical to the ligand (ELF-1) for the Mek-4 and Sek receptor protein-tyrosine kinases. of outstanding interest J Biol Chem. 270:1995;3467-3470 A methodologically detailed example of the identification of an unknown ligand by expression cloning with a receptor immunoadhesin.
17. Winslow JW, Moran P, Valverde J, Shih A, Yuan JQ, Wong SC, Tsai SP, Goddard A, Henzel WJ, Hefti F, et al. Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor involved in axon bundle formation. Neuron. 14:1995;973-981.
18. Ohashi K, Nagata K, Toshima J, Nakano T, Arita H, Tsuda H, Suzuki K, Mizuno K. Stimulation of Sky receptor tyrosine kinase by the product of growth arrest-specific gene 6. J Biol Chem. 270:1995;22681-22684.
19. Jing S, Wen D, Yu Y, Holst P, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, et al. GDNF-Induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell. 85:1996;1113-1124.
20. Peles E, Nativ M, Campbell P, Sakurai T, Martinez R, Lev S, Clary D, Schilling J, Barnea G, Plowman G. The carbonic anhydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal cell recognition molecule contactin. Cell. 82:1995;251-260.
21. Keino-Masu K, Masu M, Hinck L, Leonardo E, Chan S, Culotti J, Tessier-Lavigne M. Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell. 87:1996;175-185.
22. Meng Y, Singh N, Wong W. Binding of cynomolgus monkey IgE to a humanized anti-human IgE antibody and human high affinity IgE receptor. Mol Immunol. 33:1996;635-642.
23. Winter C, Wagtmann N, Long E, Wiley D. Direct binding of a soluble natural killer cell inhibitory receptor to a soluble human leukocyte antigen-Cw4 class I major histocompatibility complex molecule. Proc Natl Acad Sci. 93:1996;7178-7183.
24. Sun Q, DeLisser H, Zukowski M, Paddock C, Albelda S, Newman P. Individually distinct Ig homology domains in PECAM-1 regulate homophilic binding and modulate receptor affinity. of special interest J Biol Chem. 271:1996;11090-11098 The binding of PECAM-1 immunoadhesin to transfected cells expressing deletion mutants of the PECAM-1 extracellular region is used to determine which of the Ig-like domains of PECAM-1 are required for homophilic association.
25. Nagata S, Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
26. Brunner T, Mogil R, LaFace D, Yoo N, Mahboubl A, Echeverrl F, Martin S, Force W, Lynch D, Ware C, Green D. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:1995;441-444.
27. Dhein J, Walczak H, Baumler C, Debatin K-M, Krammer PH. Autocrine T-cell suicide mediated by APO-1(Fas/CD95). Nature. 373:1995;438-441.
28. Ju ST, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:1995;444-448.
29. Montel A, Bochan M, Hobbs J, Lynch D, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol. 166:1995;236-246.
30. Liles W, Kiener P, Ledbetter J, Aruffo A, Klebanoff S. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med. 184:1996;429-440.
31. Tewari M, Dixit V. Recent advances in tumor necrosis factor and CD40 signaling. Curr Opin Genet Dev. 6:1996;39-44.
32. Grammer A, Bergman M, Miura Y, Fujita K, Davis L, Lipsky P. The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol. 154:1995;4996-5010.
33. Yang Y, Wilson J. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 273:1996;1862-1864.
34. Grewal I, Foellmer H, Grewal K, Xu J, Hardardottir F, Baron J, Janeway C Jr, Flavell R. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science. 273:1996;1864-1867.
35. McMahon S, Bennett D, Priestley J, Shelton D. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med. 1:1995;774-780.
36. Figurov A, Pozzo-Miller L, Olafsson P, Wang T, Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. of special interest Nature. 381:1996;706-709 The function of neurotrophins was previously believed to be restricted to affecting neuron survival. TrkB immunoadhesin is used in this study to demonstrate that BDNF has an additional function, namely regulation of LTP in developing and adult hippocampus.
37. Ashkenazi A. Cytokine neutralisation as a potential therapeutic approach for SIRS and shock. J Biotech Healthcare. 1:1994;197-206.
38. 1 immunoadhesin in a primate model for sepsis.
39. Fisher C, Agosti J, Opal S, Lowry S, Balk R, Sandoff J, Abraham E, Schein R, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 334:1996;1697-1702.
40. 1) in the treatment of severe sepsis and septic shock [abstract]. Ninth European Conference on Intensive Care Medicine. 1996 Sept 24-28;. Glasgow, UK.
41. Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, Cohen J. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med. 180:1994;2173-2179.
42. 1-treated and TNFR1-deficient mice. J Immunol. 157:1996;3178-3182.
43. Komer H, Goodsall A, Lemckert F, Scallon B, Ghrayeb J, Ford A, Sedgwick J. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. of outstanding interest Proc Natl Acad Sci. 92:1995;11066-11070 TNFR1 immunoadhesin is shown to prevent clinical signs of experimental autoimmune encephalomyelitis without affecting the number of T cells that infiltrate the central nervous system. This provides evidence for a direct effector role of TNF in autoimmune tissue damage.
44. Gater P, Wasserman M, Paciorek P, Renzetti L. Inhibition of Sephadex-induced lung injury in the rat by Ro 45-2081, a tumor necrosis factor receptor fusion protein. Am J Respir Cell Mol Biol. 14:1996;454-460.
45. Lukacs N, Strieter R, Chensue S, Widmer M, Kunkel S. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol. 154:1995;5411-5417.
46. Dick A, McMenamin PG, Korner H, Scallon B, Ghrayeb J, Forrester J, Sedgwick J. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol. 26:1996;1018-1025.
47. Linsley P, Ledbetter J, Peach R, Bajorath J. CD28/CTLA-4 receptor structure, binding stoichlometry and aggregation during T-cell activation. Res Immunol. 146:1995;130-140.
48. Cross A, Girard T, Giacoletto K, Evans R, Keeling R, Lin R, Trotter J, Karr R. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest. 95:1995;2783-2789.
49. Larsen C, Elwood E, Alexander D, Ritchie S, Hendrix R, Tucker-Burden C, Cho H, Aruffo A, Hollenbaugh D, Linsley P, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. of outstanding interest Nature. 381:1996;434-438 Blockade of either CD28-B7 or CD40-CD40L interactions is not sufficient to permit engraftment of highly immunogenic allografts. This paper demonstrates that the combination of CTLA-4 immunoadhesin and anti-CD40L monoclonal antibody allows long-term acceptance of such allografts.
50. 1 fusion protein prolongs primate cardiac allograft survival. Transplantation. 61:1996;356-363.